World News: 13:00 GMT Friday 9th November 2018. [Spring Bank Pharmaceuticals, Inc. via Globe Newswire via SPi World News]
HOPKINTON, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that principal investigators for the ongoing Phase 2 ACHIEVE trial examining the use of inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV) will present additional inarigivir results in two presentations, one oral presentation and one poster of distinction, at the American Association for the Study of Liver Disease (AASLD) conference (The Liver Meeting®) held from Nov. 9-13, 2018 in San Francisco. Spring Bank is developing inarigivir, an orally-administered selective immunomodulator, as a potential backbone in a combinatorial treatment for chronic HBV, with a goal to accelerate and substantially increase functional cure rates in a simple, safe and selective manner.
In the poster of distinction presentation titled , Professor Stephen Locarnini, Head of Research & Molecular Development at the Victorian Infectious Diseases Reference Laboratory and Principal Investigator of the Virology Core for the ACHIEVE trial, will present data on the direct acting anti-viral (DAA) effect of inarigivir on HBV viral replication. studies in HBV cell culture systems have demonstrated that inarigivir has the ability to prevent viral replication by inhibiting HBV replication at the level of reverse transcription and/or blocking priming or subsequent primer translocation within the viral nucleocapsid, which appears independent of the RIG-I mediated activation of IRF-3 and cytokine activation. “The unique and novel DAA effect of inarigivir involves its interaction with the pregenomic RNA without preventing encapsidation like a core protein allosteric modulator (CpAM) or chain termination as seen with nucleoside/nucleotide inhibitors,” stated Professor Locarnini. “This inarigivir DAA effect and the RIG-I mediated immune activation have the potential to enhance anti-viral efficacy with both CpAMs and nucleotide/nucleoside inhibitors, and we await further clinical studies.”
In the oral presentation titled Professor M.F. Yuen, Chief of Gastroenterology and Hepatology, University of Hong Kong, and Principal Investigator for the ACHIEVE trial, will show the full 24-week clinical and virological data from the 25mg, 50mg and 100mg cohorts of inarigivir monotherapy, including sequential dosing data following the switch from inarigivir to tenofovir disoproxil fumarate (Viread®). The data demonstrate a dose dependent potent anti-viral effect of inarigivir on HBV DNA with reduction of up to 2.75log at inarigivir 100mg and similar reductions in HBV RNA. Professor Yuen’s presentation will also highlight the reduction in HBsAg in 13 predefined (HBsAg reduction > 0.5log) responder patients (7 HBeAg negative, 6 HBeAg positive) with a mean reduction of 0.8log (range 0.5log – 1.4log). Predictive factors for anti-viral response to inarigivir monotherapy include HBeAg negative status, baseline HBsAg concentration, baseline serum IP-10 and reduction in IP-10 during the first 12 weeks of inarigivir monotherapy.
“The dose dependent anti-viral response to inarigivir has continued through the 100mg daily dose cohort and the HBsAg reduction in almost 30% of patients treated in the first three cohorts is unique to inarigivir amongst approved and investigational oral HBV anti-virals. Interestingly, new data from the ACHIEVE trial on predictors provides evidence that HBsAg burden ( > 4log), a key inhibitor of the immune response, reduces anti-viral efficacy and that increased serum IP-10, a marker of immune activation in HBV, is a positive predictor for anti-viral response as previously reported for interferon therapy,” stated Professor Yuen.
A copy of the presentation materials can be accessed by visiting the and section of the Spring Bank Pharmaceuticals website after the presentations conclude.
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof. Spring Bank anticipates that subsequent events and developments will cause Spring Bank’s views to change. However, while Spring Bank may elect to update these forward-looking statements at some point in the future, Spring Bank specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spring Bank’s views as of any date after the date hereof.
LifeSci Advisors, LLC Ashley R. Robinson (617) 535-7742
Source: Spring Bank Pharmaceuticals
Globe Newswire: 13:00 GMT Friday 9th November 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.